A method of preventing dialysis shift or renal death includes administering to a primary glomerular disease or nephrosclerosis patient with a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl a sustained-release preparation including, as an active ingredient, a compound represented by formula (I):

##STR00001##

wherein R represents hydrogen or a pharmacologically acceptable cation, such that the compound represented by formula (I) is administered at 220 to 260 μg per day.

A method of preventing dialysis shift or renal death includes administering to a primary glomerular disease or nephrosclerosis patient with a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl a sustained-release preparation including, as an active ingredient, a compound represented by formula (I):

##STR00001##

wherein R represents hydrogen or a pharmacologically acceptable cation, such that the compound represented by formula (I) is administered at 220 to 260 μg per day.

A method of preventing dialysis shift or renal death includes administering to a primary glomerular disease or nephrosclerosis patient with a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl a sustained-release preparation including, as an active ingredient, a compound represented by formula (I):

##STR00001##

wherein R represents hydrogen or a pharmacologically acceptable cation, such that the compound represented by formula (I) is administered at 220 to 260 μg per day.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

Compositions for the diagnosis and treatment of asthma are disclosed. In accordance with the present invention, a method for detecting, diagnosing and/or treating asthma in a human subject of African descent is provided. An exemplary method comprises detecting at least one single nucleotide polymorphism (SNP) listed in Table I or a SNP in linkage disequilibrium with one or more of the SNPs selected from rs2529168, rs2529136, rs2429063, rs2529155, 7:21303293, rs2700292, rs2700296, 7:21328865, rs10267234, and rs150512506 or a SNP in LD with any of said SNPs, in a nucleic acid sample from the subject, wherein detection is correlated with an increased risk, susceptibility, or predisposition to asthma.

Compositions for the diagnosis and treatment of asthma are disclosed. In accordance with the present invention, a method for detecting, diagnosing and/or treating asthma in a human subject of African descent is provided. An exemplary method comprises detecting at least one single nucleotide polymorphism (SNP) listed in Table I or a SNP in linkage disequilibrium with one or more of the SNPs selected from rs2529168, rs2529136, rs2429063, rs2529155, 7:21303293, rs2700292, rs2700296, 7:21328865, rs10267234, and rs150512506 or a SNP in LD with any of said SNPs, in a nucleic acid sample from the subject, wherein detection is correlated with an increased risk, susceptibility, or predisposition to asthma.

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I.sub.2 (PGI.sub.2).

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I.sub.2 (PGI.sub.2).